YouTube · Q2 2026 · 2026-08-09
UTHR · NasdaqGS
United Therapeutics Corporation
Drug Manufacturers - Specialty & Generic · United States
USD 494.63-0.5% daily changeQuote 2026-09-18 · USD
- Market cap (USD)
- US$21.22B
- Trailing P/E
- 17.73x
- Forward P/E
- 16.47x
- Quarterly revenue growth
- -1.9%
- Trailing net margin
- 41.6%
- Indicated dividend yield
- —
Snapshot 2026-09-20 · Latest financial period 2026-06-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.
Next earnings: 2026-10-28 (provider estimate, not issuer-confirmed).
Company background
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
Company websiteQ2 2026
Go beyond the headline.
United Therapeutics (UTHR): $7.27 Beat Consensus. Operating Income Fell 9%.
Published 2026-08-05
Comparable businesses
UTHR peer comparison
Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.
| Metric | UTHRUnited Therapeutics CorporationSnapshot 2026-09-20Financial period: 2026-06-30 | VTRSViatris Inc.Snapshot 2026-09-20Financial period: 2026-06-30 | ZTSZoetis Inc.Snapshot 2026-09-21Financial period: 2026-06-30 | Peer medianSimilar-size peers only |
|---|---|---|---|---|
| Market capMarket value, converted to USD | US$21.22B | US$19.47B | US$29.50B | US$24.49Bn=2 |
| Forward P/EProvider forward earnings estimate | 16.47x | 6.37x | 10.93x | 8.65xn=2 |
| EV / EBITDAEnterprise value / trailing EBITDA | 12.40x | 7.36x | 9.12x | 8.24xn=2 |
| Revenue growthLatest quarter vs prior-year quarter | -1.9% | 4.9% | -0.2% | 2.4%n=2 |
| Operating marginLatest reported quarter | 42.2% | 12.6% | 40.7% | 26.6%n=2 |
| Free cash flow yieldTrailing cash flow / market cap | 2.6% | 13.8% | 6.8% | 10.3%n=2 |
| Net debt / EBITDANet debt / trailing EBITDA | -1.78x | 2.82x | 1.86x | 2.34xn=2 |
| Debt / equityTotal debt / positive book equity | — | 0.96x | — | — |
| Trailing P/ETrailing twelve-month earnings | 17.73x | — | 11.65x | — |
| Price / bookPrice / positive book equity per share | 3.30x | 1.35x | — | — |
| EV / salesEnterprise value / trailing revenue | 5.88x | 2.14x | 3.89x | 3.02xn=2 |
| Earnings growthLatest quarter vs prior-year quarter | 13.4% | — | 1.2% | — |
| Gross marginTrailing twelve months | 86.1% | 40.3% | 71.7% | 56.0%n=2 |
| Net marginTrailing twelve months | 41.6% | -2.8% | 27.7% | 12.4%n=2 |
| Return on equityProvider trailing return; positive equity only | 19.3% | -2.8% | — | — |
| Free cash flow marginTrailing free cash flow / revenue | 17.7% | 18.2% | 21.2% | 19.7%n=2 |
| Dividend yieldIndicated annual dividend / price | — | 2.8% | 3.0% | 2.9%n=2 |
| Earnings payoutProvider trailing dividend payout | 0.0% | 960.0% | 33.6% | 496.8%n=2 |
| Current ratioCurrent assets / current liabilities | 5.73x | 1.58x | 3.08x | 2.33xn=2 |
| BetaProvider historical market sensitivity | 0.56 | 0.88 | 0.73 | 0.81n=2 |
YouTube · Q2 2026 · 2026-08-09
YouTube · Q2 2026 · 2026-08-07
Comparison methodology & limitations
Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.
Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.
Reported performance
Financial trends
Periods are grouped by their ending calendar year or quarter, not identical fiscal calendars. Exact period-end dates appear in tooltips and reported figures. When reporting currencies differ and a recent captured FX rate is available, money and EPS are normalized to USD for comparison. This is not a historical FX restatement. Gaps are not estimated.
Financial statements load separately from the research page.
Source: . Window ends at the latest available reporting period.
Revenue
Reported figures
Financial data & calculation notes
Standalone charts use the stated reporting currency. When a chart comparison spans currencies, money and EPS can be normalized to USD using a recent captured FX snapshot; this is for comparison only, not a historical FX restatement. Stock-based compensation is noncash. Free cash flow is operating cash flow less capital spending, which may include capitalized software. Missing metrics are not estimated or assumed to be zero. Banking and insurance ratios require industry-specific interpretation. Latest restatements may differ from figures in older episodes.
Market context
Valuation & price history
Adjusted closing price
Price history loads separately.
Price figures
Earnings-multiple scenario
Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.
Starting assumptions, when available, use provider forward estimates as of 2026-09-20. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.
THE RESEARCH RECORD
Research history for UTHR
Q2 20262026-08-05
United Therapeutics (UTHR): $7.27 Beat Consensus. Operating Income Fell 9%.
Presentation · 2026-08-05 · YouTube